Opdivo makes rare hit in adjuvant muscle-invasive bladder cancer

As competition for earlier lines of treatment intensifies among checkpoint inhibitors, the latest data for Opdivo suggest BMS may have a window of opportunity in muscle invasive bladder cancer.

At the American Society for Clinical Oncology Genitourinary Cancers Symposium, Bristol Myers Squibb Co. (NYSE:BMY) shared data from the Phase III CheckMate-274 study showing adjuvant treatment with Opdivo nivolumab nearly doubled the disease-free survival time for high-risk muscle-invasive bladder cancer patients...